The clinical value of CTSF, FBLN1, and AKR1B10 in the diagnosis of NSCLC BM was assessed in cohort 2 comprising of 459 patients including 379 patients with NSCLC, 30 primary brain tumours (PBT), and 50 HG. This evidence concerns the gene FBLN1 and brain neoplasm.